title: Can the exome and the immunome converge on the design of efficient cancer vaccines?
abstract: Human cancers carry hundreds of non-synonymous mutations, several dozens among which may lead to the generation of tumor-specific MHC Class I-restricted epitopes. Hence every patient's tumor harbors a highly specific mutational and antigenic signature and up to 95% of these mutations are unique. This "mutanome" can be identified by deep sequencing and can be subjected to systematic analyses of the immunogenicity of mutated proteins/peptides. We anticipate that this approach will lead to individualized immunotherapies by means of tailored vaccines.
authors.affiliation: INSERM, U848; Villejuif, France ; Metabolomics Platform; Institut Gustave Roussy; Villejuif, France ; Centre de Recherche des Cordeliers; Paris, France ; Pôle de Biologie; Hôpital Européen Georges Pompidou; AP-HP; Paris, France ; Université Paris Descartes; Faculté de Médecine; Paris, France.
authors.forename: Guido
authors.initials: G
authors.lastname: Kroemer
authors.forename: Laurence
authors.initials: L
authors.lastname: Zitvogel